Category: Misc

• A moving target for drug discovery: Structure activity relationship and many genome (de)stabilizing functions of the RAD52 protein.
• Bhat DS, Spies MA, Spies M.
• DNA Repair (Amst). 2022 Oct 27;120:103421. doi: 10.1016/j.dnarep.2022.103421. Epub ahead of print.

• PMID: 36327799
• PubMed abstract
• Source abstract

• Review

• The DNA damage induced immune response: Implications for cancer therapy.
• Barros EM, McIntosh SA, Savage KI.
• DNA Repair (Amst). 2022 Oct 3;120:103409. doi: 10.1016/j.dnarep.2022.103409. Epub ahead of print.

• PMID: 36308822
• PubMed abstract

• Review
• Free Full Text

• Single-cell genomic variation induced by mutational processes in cancer.
• Funnell T, O'Flanagan CH, Williams MJ, McPherson A, McKinney S, Kabeer F, Lee H, Salehi S, Vázquez-García I, Shi H, Leventhal E, Masud T, Eirew P, Yap D, Zhang AW, Lim JLP, Wang B, Brimhall J, Biele J, Ting J, Au V, Van Vliet M, Liu YF, Beatty S, Lai D, Pham J, Grewal D, Abrams D, Havasov E, Leung S, Bojilova V, Moore RA, Rusk N, Uhlitz F, Ceglia N, Weiner AC, Zaikova E, Douglas JM, Zamarin D, Weigelt B, Kim SH, Da Cruz Paula A, Reis-Filho JS, Martin SD, Li Y, Xu H, de Algara TR, Lee SR, Llanos VC, Huntsman DG, McAlpine JN; IMAXT Consortium, Shah SP, Aparicio S.
• Nature. 2022 Oct 26. doi: 10.1038/s41586-022-05249-0. Epub ahead of print.

• PMID: 36289342
• PubMed abstract

• Free Full Text

• How should we address the inevitable harms from non-negligent variant reclassification in predictive genetic testing?
• Rashkin M, Kingham K, Lara-Otero , Mckenna M, Villiers J, Worthington MM, Prince A.
• J Genet Couns. 2022 Oct 19. doi: 10.1002/jgc4.1638. Epub ahead of print.

• Source abstract

• Free Full Text

• Genomic and expressional dynamics of ovarian cancer cell lines in PARPi treatment revealed mechanisms of acquired resistance.
• Cheng A, Rao Q, Liu Y, Huo C, Lin Z, Lu H.
• Gynecol Oncol. 2022 Oct 18:S0090-8258(22)01888-1. doi: 10.1016/j.ygyno.2022.10.011. Epub ahead of print.

• Source abstract

• Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984.
• Kim JW, McKay RR, Radke MR, Zhao S, Taplin ME, Davis NB, Monk P, Appleman LJ, Lara PN Jr, Vaishampayan UN, Zhang J, Paul AK, Bubley G, Van Allen EM, Unlu S, Huang Y, Loda M, Shapiro GI, Glazer PM, LoRusso PM, Ivy SP, Shyr Y, Swisher EM, Petrylak DP.
• J Clin Oncol. 2022 Oct 18:JCO2102947. doi: 10.1200/JCO.21.02947. Epub ahead of print.

• PMID: 36256912
• PubMed abstract

• Free Full Text

Related:

Identifier: NCT02893917: Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer. (ClinicalTrials.gov . Accessed 2022 Oct 19.)

• Dr. Karlan on Current Research Evaluating PARP Inhibitor Combination Therapy in Ovarian Cancer.
• Karlan BY.
• OncLive. OncLive TV. 2022 Oct 18.

• Review
• Free video

• Combined inhibition of PARP and EZH2 for cancer treatment: Current status, opportunities, and challenges.
• Zhang X, Huo X, Guo H, Xue L.
• Front Pharmacol. 2022 Oct 3;13:965244. doi: 10.3389/fphar.2022.965244.

• PMID: 36263120
• PubMed abstract

• Review
• Free PMC article
• Free Full Text

• IN VIVO ASSIGNMENT OF METHYLMALONIC ACID IN BREAST TISSUE USING 2D MAGNETIC RESONANCE SPECTROSCOPY AND RELATIONSHIP WITH BREAST DENSITY, MENOPAUSAL STATUS AND CANCER RISK.
• Santamaría G, Naude N, Bennett I, Vosburgh K, Ganau S, Bargalló X, Malycha P, Mountford C.
• NMR Biomed. 2022 Oct 19:e4851. doi: 10.1002/nbm.4851. Epub ahead of print.

• PMID: 36259358
• PubMed abstract
• Source abstract

• RAD6 inhibition enhances paclitaxel sensitivity of triple negative breast cancer cells by aggravating mitotic spindle damage.
• Haynes BM, Cunningham K, Shekhar MPV.
• BMC Cancer. 2022 Oct 18;22(1):1073. doi: 10.1186/s12885-022-10119-z.

• PMID: 36258187
• PubMed abstract

• Free Full Text

• Longitudinal Serum Protein Analysis of Women with a High Risk of Developing Breast Cancer Reveals Large Interpatient Versus Small Intrapatient Variations: First Results from the TESTBREAST Study.
• Hagenaars SC, Dekker LJM, Ravesteijn B, van Vlierberghe RLP, Romijn FPHTM, Verhoeff L, Witkamp AJ, Schenk KE, Keymeulen KBIM, Menke-Pluijmers MBE, Dassen AE, Kortmann BA, de Vries J, Rutgers EJT, van der Burgt YEM, Meershoek-Klein Kranenbarg E, Cobbaert CM, Luider TM, Mesker WE, Tollenaar RAEM.
• Int J Mol Sci. 2022 Oct 17;23(20):12399. doi: 10.3390/ijms232012399.

• Source abstract

• Free Full Text

• Ubiquitinated PCNA drives USP1 synthetic lethality in cancer.
• Simoneau A, Engel JL, Bandi M, Lazarides K, Liu S, Meier SR, Choi AH, Zhang H, Shen B, Martires L, Gotur D, Pham TV, Li F, Gu L, Gong S, Zhang M, Wilker E, Pan X, Whittington DA, Throner S, Maxwell JP, Chen Y, Yu Y, Huang A, Andersen JN, Feng T.
• Mol Cancer Ther. 2022 Oct 12:MCT-22-0409. doi: 10.1158/1535-7163.MCT-22-0409. Epub ahead of print.

• PMID: 36228090
• PubMed abstract
• Source abstract

• Free Full Text (PDF)

• Distinct roles of treatment schemes and BRCA2 on the restoration of homologous recombination DNA repair and PARP inhibitor resistance in ovarian cancer.
• Huang TT, Burkett SS, Tandon M, Yamamoto TM, Gupta N, Bitler BG, Lee JM, Nair JR.
• Oncogene. 2022 Oct 12. doi: 10.1038/s41388-022-02491-8. Epub ahead of print.

• PMID: 36224341
• PubMed abstract
• Source abstract

• Genetic Testing Challenges in Oncology: Missed Variant Update Delays Li-Fraumeni Diagnosis.
• Ray T.
• Precision Oncology News. 2022 Oct 12.

• Case report
• Free Full Text

Related:

Special article:

Is there a duty to reinterpret genetic data? The ethical dimensions.

• PMID: 31616070
• PubMed abstract
• Free Full Text

• PARP-inhibition reprograms macrophages toward an anti-tumor phenotype.
• Wang L, Wang D, Sonzogni O, Ke S, Wang Q, Thavamani A, Batalini F, Stopka SA, Regan MS, Vandal S, Tian S, Pinto J, Cyr AM, Bret-Mounet VC, Baquer G, Eikesdal HP, Yuan M, Asara JM, Heng YJ, Bai P, Agar NYR, Wulf GM.
• Cell Rep. 2022 Oct 11;41(2):111462. doi: 10.1016/j.celrep.2022.111462.

• PMID: 36223740
• PubMed abstract

• Free Full Text

• CXCR4 inhibitor, AMD3100, down-regulates PARP1 expression and Synergizes with olaparib causing severe DNA damage in BRCA-proficient triple-negative breast cancer.
• Xie XF, Wu NQ, Wu JF, Zhang GL, Guo JF, Chen XL, Du CW.
• Cancer Lett. 2022 Oct 6:215944. doi: 10.1016/j.canlet.2022.215944. Epub ahead of print.

• PMID: 36209974
• PubMed abstract
• Source abstract

• Developing theory-driven narrative messages with personal stories: A step-by-step guide.
• Conley CC, Davidson LG, Scherr CL, Dean M.
• Psychooncology. 2022 Oct 7. doi: 10.1002/pon.6047. Epub ahead of print.

• PMID: 36205027
• PubMed abstract
• Source abstract